Massive Bio vs Mendel
One of these sells enrolments and the other sells the capability underneath them, which is the distinction to settle before comparing anything else. Massive Bio is an oncology matching and enrolment platform: it extracts structured information from records, matches against a very large active trial list, has certified case managers audit every match, and has peer reviewed prospective evidence for the product itself. Mendel is a chart abstraction platform whose reasoning serves prescreening, cohort building and observational research alike, with a specific architecture combining language models and symbolic reasoning precisely because generation alone produces confident errors, and it can run inside your own environment. If the mandate is enrol more oncology patients this year, Massive Bio is pointed at exactly that. If it is stop paying clinicians to read charts, Mendel is the broader purchase.
- Human oversight is structural rather than asserted, with certified oncology case managers auditing every generated match before it is acted on.
- Peer reviewed prospective evidence exists for the matching product itself, which is rare in this category and rarer still for a company of this size.
- It reaches patients directly as well as through sites, so a patient whose oncologist has no trial programme is not excluded by their institution's capability.
- Chart abstraction is the underlying capability rather than matching alone, so the same platform serves cohort building, observational studies and prescreening rather than one workflow.
- The architecture is specific and defensible: language models paired with symbolic reasoning over a clinical hypergraph, chosen because generation alone produces confident abstraction errors.
- It can be hosted inside the customer's own environment, which is the strongest residency position among the trial vendors here and often the deciding factor for an academic centre.
Side by Side
| Axis | M Massive Bio |
M Mendel |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Trials AI page.
These products are adjacent rather than identical: one is a matching and enrolment service for oncology, the other is a chart abstraction platform of which prescreening is one application, so a buyer comparing them should establish whether they are buying enrolment outcomes or a reusable abstraction capability. Neither vendor publishes a security attestation or trust centre and neither publishes pricing. Neither publishes a false negative rate for eligibility screening, which is the number that matters most, since an eligible patient never surfaced is invisible to every metric either vendor reports.